Title |
Azilsartan as a Potent Antihypertensive Drug with Possible Pleiotropic Cardiometabolic Effects: A Review Study
|
---|---|
Published in |
Frontiers in Pharmacology, August 2016
|
DOI | 10.3389/fphar.2016.00235 |
Pubmed ID | |
Authors |
Georgios Georgiopoulos, Vasiliki Katsi, Dimitrios Oikonomou, Georgia Vamvakou, Evangelia Koutli, Aggeliki Laina, Constantinos Tsioufis, Petros Nihoyannopoulos, Dimitrios Tousoulis |
Abstract |
Hypertension related cardiovascular (CV) complications could be amplified by the presence of metabolic co-morbidities. Azilsartan medoxomil (AZL-M) is the eighth approved member of angiotensin II receptor blockers (ARBs), a drug class of high priority in the management of hypertensive subjects with diabetes mellitus type II (DMII). Under this prism, we performed a systematic review of the literature for all relevant articles in order to evaluate the efficacy, safety, and possible clinical role of AZL-M in hypertensive diabetic patients. AZL-M was found to be more effective in terms of reducing indices of blood pressure over alternative ARBs or angiotensin-converting enzyme (ACE) inhibitors with minimal side effects. Preclinical studies have established pleiotropic effects for AZL-M beyond its primary antihypertensive role through differential gene expression, up-regulation of membrane receptors and favorable effect on selective intracellular biochemical and pro-atherosclerotic pathways. Indirect but accumulating evidence from recent literature supports the efficacy and safety of AZL-M among diabetic patients. However, no clinical data exist to date that evince a beneficial role of AZL-M in patients with metabolic disorders on top of its antihypertensive effect. Further clinical studies are warranted to assess the pleiotropic cardiometabolic benefits of AZL-M that are derived from preclinical research. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Switzerland | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 21 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 3 | 14% |
Student > Master | 2 | 10% |
Student > Bachelor | 2 | 10% |
Student > Postgraduate | 2 | 10% |
Researcher | 2 | 10% |
Other | 5 | 24% |
Unknown | 5 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 5 | 24% |
Biochemistry, Genetics and Molecular Biology | 3 | 14% |
Social Sciences | 2 | 10% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
Agricultural and Biological Sciences | 1 | 5% |
Other | 3 | 14% |
Unknown | 6 | 29% |